M. Keir

Immunology · 2007–2008

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

Whom M. Keir trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Taku Okazaki
  2. G. Freeman

Who trusts M. Keir overall

  1. A. Schietinger
  2. D. Pardoll
  3. B. Fife
  4. S. Topalian
  5. Kristen E. Pauken
  6. P. Greenberg
  7. Anand Rotte
  8. E. Buchbinder
  9. James L. Riley
  10. Lieping Chen

Papers from M. Keir's perspective

Ordered by how strongly the researchers M. Keir trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
  2. B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells (Journal of Experimental Medicine)
  3. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
  4. PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
  5. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
  6. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
  7. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 (Journal of Immunology)
  8. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (Cancer Research)
  9. SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
  10. PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 (European Journal of Immunology)

Their papers